CINCINNATI--(BUSINESS WIRE)--Eccrine Systems, Inc. announced today that it is collaborating with Maxim Integrated Products, Inc. (NASDAQ: MXIM) on the development and integration of analog signal processing technologies to drive Eccrine's sweat sensing platform.
Eccrine is pioneering the field of pharmacoeccrinology, a non-invasive approach to precision medicine based on continuous measurements of drug and biomarker levels excreted in locally stimulated sweat.
Personal drug response data is derived from sweat using Eccrine's electrochemical aptamer-based (EAB) sensor platform.
Continuous measurement of these molecules identifies patient responses to drug therapy with the promise of helping prescribers optimize individual dosing requirements more rapidly and cost-effectively.
According to Gavi Begtrup, Ph.D., Chief Executive Officer of Eccrine, "Reducing Eccrine's EAB sensor system to a convenient, cost-effective, wearable format requires transducing small currents in a noisy environment with low power consumption and high fidelity, all of which are Maxim's strengths.
It's great to be collaborating with the Maxim team as we invent and develop the use of those sensors for precision pharmacotherapy."